Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.10
ALKS's Cash to Debt is ranked lower than
72% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. ALKS: 2.10 )
Ranked among companies with meaningful Cash to Debt only.
ALKS' s 10-Year Cash to Debt Range
Min: 0.04  Med: 1.52 Max: No Debt
Current: 2.1
Equity to Asset 0.74
ALKS's Equity to Asset is ranked higher than
57% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ALKS: 0.74 )
Ranked among companies with meaningful Equity to Asset only.
ALKS' s 10-Year Equity to Asset Range
Min: -0.15  Med: 0.60 Max: 0.9
Current: 0.74
-0.15
0.9
F-Score: 6
Z-Score: 11.86
M-Score: -2.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -15.17
ALKS's Operating margin (%) is ranked higher than
63% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. ALKS: -15.17 )
Ranked among companies with meaningful Operating margin (%) only.
ALKS' s 10-Year Operating margin (%) Range
Min: -331.3  Med: -34.92 Max: 41.29
Current: -15.17
-331.3
41.29
Net-margin (%) -5.60
ALKS's Net-margin (%) is ranked higher than
64% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. ALKS: -5.60 )
Ranked among companies with meaningful Net-margin (%) only.
ALKS' s 10-Year Net-margin (%) Range
Min: -296.89  Med: -30.11 Max: 69.37
Current: -5.6
-296.89
69.37
ROE (%) -2.66
ALKS's ROE (%) is ranked higher than
70% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. ALKS: -2.66 )
Ranked among companies with meaningful ROE (%) only.
ALKS' s 10-Year ROE (%) Range
Min: -288.88  Med: -10.99 Max: 65.64
Current: -2.66
-288.88
65.64
ROA (%) -1.94
ALKS's ROA (%) is ranked higher than
71% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. ALKS: -1.94 )
Ranked among companies with meaningful ROA (%) only.
ALKS' s 10-Year ROA (%) Range
Min: -38.95  Med: -8.57 Max: 27.26
Current: -1.94
-38.95
27.26
ROC (Joel Greenblatt) (%) -2.52
ALKS's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. ALKS: -2.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALKS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -412.33  Med: -38.93 Max: 131.93
Current: -2.52
-412.33
131.93
Revenue Growth (3Y)(%) 29.80
ALKS's Revenue Growth (3Y)(%) is ranked higher than
84% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. ALKS: 29.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALKS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -22  Med: 11.30 Max: 69.1
Current: 29.8
-22
69.1
EPS Growth (3Y)(%) -24.10
ALKS's EPS Growth (3Y)(%) is ranked lower than
71% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. ALKS: -24.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALKS' s 10-Year EPS Growth (3Y)(%) Range
Min: -24.1  Med: 16.80 Max: 224
Current: -24.1
-24.1
224
» ALKS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ALKS Guru Trades in Q2 2014

Ken Fisher 55,309 sh (New)
Jim Simons 214,686 sh (+302.71%)
Vanguard Health Care Fund 6,135,913 sh (+18.45%)
Murray Stahl 25,000 sh (unchged)
John Burbank Sold Out
Pioneer Investments 175,517 sh (-2.90%)
Jeff Auxier 28,851 sh (-3.35%)
» More
Q3 2014

ALKS Guru Trades in Q3 2014

Ken Fisher 97,264 sh (+75.86%)
Vanguard Health Care Fund 6,223,083 sh (+1.42%)
Pioneer Investments 292,728 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 28,851 sh (unchged)
Jim Simons 155,786 sh (-27.44%)
» More
Q4 2014

ALKS Guru Trades in Q4 2014

Ken Fisher 107,164 sh (+10.18%)
Vanguard Health Care Fund 6,226,383 sh (+0.05%)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 27,851 sh (-3.47%)
Pioneer Investments 281,576 sh (-3.81%)
Jim Simons 63,986 sh (-58.93%)
» More
Q1 2015

ALKS Guru Trades in Q1 2015

Jim Simons 198,686 sh (+210.51%)
Vanguard Health Care Fund 6,229,583 sh (+0.05%)
Ken Fisher 107,164 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Pioneer Investments 252,166 sh (-10.44%)
Jeff Auxier 24,051 sh (-13.64%)
» More
» Details

Insider Trades

Latest Guru Trades with ALKS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 72.46
ALKS's Forward P/E is ranked lower than
87% of the 168 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. ALKS: 72.46 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 6.59
ALKS's P/B is ranked lower than
64% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. ALKS: 6.59 )
Ranked among companies with meaningful P/B only.
ALKS' s 10-Year P/B Range
Min: 1.66  Med: 4.26 Max: 379.8
Current: 6.59
1.66
379.8
P/S 14.43
ALKS's P/S is ranked lower than
51% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. ALKS: 14.43 )
Ranked among companies with meaningful P/S only.
ALKS' s 10-Year P/S Range
Min: 2.19  Med: 7.06 Max: 22.47
Current: 14.43
2.19
22.47
POCF 573.36
ALKS's POCF is ranked lower than
97% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 31.61 vs. ALKS: 573.36 )
Ranked among companies with meaningful POCF only.
ALKS' s 10-Year POCF Range
Min: 8.73  Med: 32.17 Max: 915.5
Current: 573.36
8.73
915.5
EV-to-EBIT -878.45
ALKS's EV-to-EBIT is ranked lower than
465% of the 225 Companies
in the Global Biotechnology industry.

( Industry Median: 29.73 vs. ALKS: -878.45 )
Ranked among companies with meaningful EV-to-EBIT only.
ALKS' s 10-Year EV-to-EBIT Range
Min: -1059.6  Med: -15.75 Max: 628
Current: -878.45
-1059.6
628
Current Ratio 8.79
ALKS's Current Ratio is ranked higher than
70% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. ALKS: 8.79 )
Ranked among companies with meaningful Current Ratio only.
ALKS' s 10-Year Current Ratio Range
Min: 2.01  Med: 6.30 Max: 15.4
Current: 8.79
2.01
15.4
Quick Ratio 8.36
ALKS's Quick Ratio is ranked higher than
70% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. ALKS: 8.36 )
Ranked among companies with meaningful Quick Ratio only.
ALKS' s 10-Year Quick Ratio Range
Min: 1.95  Med: 6.14 Max: 15.4
Current: 8.36
1.95
15.4
Days Inventory 108.67
ALKS's Days Inventory is ranked higher than
54% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. ALKS: 108.67 )
Ranked among companies with meaningful Days Inventory only.
ALKS' s 10-Year Days Inventory Range
Min: 43.09  Med: 93.78 Max: 166.33
Current: 108.67
43.09
166.33
Days Sales Outstanding 79.75
ALKS's Days Sales Outstanding is ranked lower than
63% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. ALKS: 79.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALKS' s 10-Year Days Sales Outstanding Range
Min: 27.46  Med: 79.03 Max: 128.45
Current: 79.75
27.46
128.45

Valuation & Return

vs
industry
vs
history
Price/Net Cash 38.46
ALKS's Price/Net Cash is ranked lower than
87% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 8.97 vs. ALKS: 38.46 )
Ranked among companies with meaningful Price/Net Cash only.
ALKS' s 10-Year Price/Net Cash Range
Min: 3.39  Med: 12.22 Max: 113.05
Current: 38.46
3.39
113.05
Price/Net Current Asset Value 18.78
ALKS's Price/Net Current Asset Value is ranked lower than
78% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. ALKS: 18.78 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALKS' s 10-Year Price/Net Current Asset Value Range
Min: 2.4  Med: 9.43 Max: 343
Current: 18.78
2.4
343
Price/Tangible Book 10.86
ALKS's Price/Tangible Book is ranked lower than
72% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. ALKS: 10.86 )
Ranked among companies with meaningful Price/Tangible Book only.
ALKS' s 10-Year Price/Tangible Book Range
Min: 1.8  Med: 8.45 Max: 336
Current: 10.86
1.8
336
Price/Projected FCF 7.35
ALKS's Price/Projected FCF is ranked lower than
66% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ALKS: 7.35 )
Ranked among companies with meaningful Price/Projected FCF only.
ALKS' s 10-Year Price/Projected FCF Range
Min: 2  Med: 3.55 Max: 20.95
Current: 7.35
2
20.95
Price/Median PS Value 2.05
ALKS's Price/Median PS Value is ranked lower than
75% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. ALKS: 2.05 )
Ranked among companies with meaningful Price/Median PS Value only.
ALKS' s 10-Year Price/Median PS Value Range
Min: 0.42  Med: 1.75 Max: 14.23
Current: 2.05
0.42
14.23
Earnings Yield (Greenblatt) (%) -0.10
ALKS's Earnings Yield (Greenblatt) (%) is ranked higher than
74% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. ALKS: -0.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALKS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 1.50 Max: 27.9
Current: -0.1
0.2
27.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:8AK.Germany,
Alkermes PLC is a biotechnology company. The Company is engaged in developing, manufacturing and commercializing medicines. The Company has a portfolio of commercial drug products and a clinical pipeline of product candidates that address central nervous system disorders such as addiction, schizophrenia and depression. The Company's products include CODAS, IPDAS, LinkeRx, MXDAS, NanoCrystal, SODAS, VERELAN and VIVITROL.
» More Articles for ALKS

Headlines

Articles On GuruFocus.com
wait for positive ea Apr 06 2013 
comment on ALKS Mar 09 2013 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
Opportunistic Coat-tailing Jan 05 2010 

More From Other Websites
Wall Street Is Running Out Of Ways To Make Easy Money Off Corporate Tax Loopholes Jul 01 2015
Edited Transcript of ALKS conference call or presentation 23-Jun-15 12:00pm GMT Jun 24 2015
Alkermes Plc Conference Call to Discuss Data of ALKS 3831 for Treatment of Schizophrenia scheduled... Jun 23 2015
The CEO who quit cigarettes for his stock's health Jun 19 2015
Jim Cramer's Top Takeaways: Palo Alto Networks, Tesla, Ambarella, Allergan, Wingstop, Alkermes Jun 18 2015
Jim Cramer's 'Mad Money' Recap: Thanks for Nothing, Janet Yellen Jun 17 2015
Cramer Remix: Are you smarter than Janet Yellen? Jun 17 2015
Alkermes (ALKS) in Focus: Stock Rises 10.1% in Session - Tale of the Tape Jun 17 2015
Alkermes (ALKS) Stock Gains After Announcing Presentation at Annual ASCP Meeting Jun 16 2015
Alkermes to Present Data From Late-Stage CNS Portfolio at Upcoming American Society of Clinical... Jun 16 2015
Alkermes to Present Data From Late-Stage CNS Portfolio at Upcoming American Society of Clinical... Jun 16 2015
Alkermes to Present Data From Late-Stage CNS Portfolio at Upcoming American Society of Clinical... Jun 16 2015
Aripiprazole Lauroxil Phase 3 Schizophrenia Study Results Published in Journal of Clinical... Jun 09 2015
Aripiprazole Lauroxil Phase 3 Schizophrenia Study Results Published in Journal of Clinical... Jun 09 2015
Aripiprazole Lauroxil Phase 3 Schizophrenia Study Results Published in Journal of Clinical... Jun 09 2015
Coverage initiated on Alkermes by Guggenheim Jun 09 2015
Alkermes’ Corporate Presentation to be Webcast At The Goldman Sachs 36th Annual Global Healthcare... Jun 02 2015
Alkermes’ Corporate Presentation to be Webcast At The Goldman Sachs 36th Annual Global Healthcare... Jun 02 2015
Alkermes’ Corporate Presentation to be Webcast At The Goldman Sachs 36th Annual Global Healthcare... Jun 02 2015
ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters... May 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK